Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease

Movement Disorders

Volumn 22, Issue 1, 2007, Pages 14-19

  Kinnunen, Esko ^a   Myllylä, Vilho ^b   Agid, Yves ^c   Damier, Philippe ^d   Vidailhet, Marie ^e   Durif, Franck ^f   Pollak, Pierre ^g   Rivier, Isabelle ^h   Verin, Marc ⁱ   Ziegler, Marc ^j   Viallet, Francois ^k   Baas, Horst ^l   Gemende, Irene ^m   Glass, Joachim ⁿ   Oertel, Wolfgang ^o   Sommer, Helma ^p   De Yebenes, Justo Garcia ^q   Kulisevsky, Jaime ^r   Tolosa, Eduardo ^s   Ahlberg, Jarl ^t   Palm, Ragnar ^u   Burgunder, Jean Marc ^v   Burkhard, Pierre ^w   Ghika, Joseph Andre ^x   Davis, Thomas ^y   Factor, Stewart ^z   Hutton, Thomas ^aa   Margolin, David ^ab   Stark, Stuart ^ac   Troung, Daniel ^ad   Wong, George ^ae   more..

^a HYVINKÄÄ HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h Centre Regional de Geriatrie   (France)

ⁱ RENNES UNIVERSITY HOSPITAL   (France)

^j Léopold Bellan Hospital   (France)

^k Pays d'Aix Hospital   (France)

^l Stadtkrankenhaus   (Germany)

^m Waldklinik Bernburg ^*  (Germany)

ⁿ Arztehaus an der Marienkirche   (Germany)

^o PHILIPPS UNIVERSITY MARBURG   (Germany)

^p Praxis für Neurologie und Psychiatrie   (Germany)

^q Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^r HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^s HOSPITAL CLÍNIC   (Spain)

^t SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^u Praktiken Ankaret   (Sweden)

^v UNIVERSITY OF BERN   (Switzerland)

^w HCU   (Switzerland)

^x LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^y VANDERBILT UNIVERSITY   (United States)

^z ALBANY MEDICAL COLLEGE   (United States)

^aa Texas Tech University Health Sciences Center   (United States)

^ab Margolin Brain Institute   (United States)

^ac Innovative Clinical Research Center   (United States)

^ad Parkinson's and Movement Disorder Institute   (United States)

^ae Cox Pharmacotherapy Research Division ^*  (United States)

more..

Author keywords

COMT inhibition; Entacapone; Motor fluctuations; Parkinson's disease; Tolcapone

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; TOLCAPONE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FALLING; FEMALE; HALLUCINATION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CASE-CONTROL STUDIES; CATECHOLS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITRILES; NITROPHENOLS; PARKINSON DISEASE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847705664     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21131     Document Type: Article

References (18)

1. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
2. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
3. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic- pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
4. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
5. Kurth MC, Adler CH, St Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
6. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Redder S. Tolcapone improves motor function in parkinsonian patients with the "wearing- off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
7. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
8. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998;55:1089-1095.
9. Koller W, Lees A, Doder M, Hely M, and the Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001;16:858-866.
10. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
11. Rinne UK, Larsen JP, Siden Å, Worm-Petersen J, the Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-1314.
12. Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M, the FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60.
13. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, the Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
14. Brooks DJ, Sagar H, the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071-1079.
15. Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 2001;24:295-299.
16. Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur Neurol 2001;46:11-16.
17. Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 1998;21(Suppl. 1):S9-S16.
18. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet 1998;352:958.